Investors sentiment decreased to 0.98 in Q4 2018. Its down 0.82, from 1.8 in 2018Q3. It dropped, as 20 investors sold Marinus Pharmaceuticals, Inc. shares while 20 reduced holdings. 19 funds opened positions while 20 raised stakes. 26.47 million shares or 18.54% more from 22.33 million shares in 2018Q3 were reported.
Franklin holds 2.32 million shares. 71,706 were accumulated by Bridgeway Capital Inc. 524,663 are held by Partner Fund Management Limited Partnership. Voya Mgmt Ltd has invested 0% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Engineers Gate Manager Ltd Partnership invested in 149,447 shares or 0.03% of the stock. Moreover, Amer Group has 0% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Spark reported 145,500 shares stake. Alpine Management Limited Liability Co holds 0.07% or 89,096 shares. Jefferies Grp Ltd Llc stated it has 1.70 million shares or 0.04% of all its holdings. Manufacturers Life Ins The owns 0% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 24,857 shares. Invesco stated it has 12,056 shares or 0% of all its holdings. Citigroup holds 9,550 shares or 0% of its portfolio. Shanda Asset Ltd holds 10,000 shares or 0.01% of its portfolio. Arrowmark Colorado Lc has invested 0% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Artal Grp Inc holds 500,000 shares or 0.05% of its portfolio.
Since January 28, 2019, it had 0 buys, and 2 sales for $33,110 activity. Another trade for 2,492 shares valued at $7,626 was made by Smith Edward F on Tuesday, January 29.
The stock of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) registered an increase of 9.97% in short interest. MRNS’s total short interest was 2.89M shares in March as published by FINRA. Its up 9.97% from 2.63M shares, reported previously. With 622,300 shares average volume, it will take short sellers 5 days to cover their MRNS’s short positions.
The stock increased 1.06% or $0.04 during the last trading session, reaching $3.83. About 1.42M shares traded or 58.03% up from the average. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has declined 28.66% since March 17, 2018 and is downtrending. It has underperformed by 33.03% the S&P500.
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company has market cap of $201.15 million. The firm is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. It currently has negative earnings. The firm is also developing ganaxolone IV formulation to treat status epilepticus.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Ratings Coverage
Among 5 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Marinus Pharmaceuticals had 9 analyst reports since February 6, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, February 27 by Ladenburg. The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) earned “Hold” rating by Mizuho on Tuesday, March 12. The firm earned “Neutral” rating on Wednesday, February 27 by Mizuho. The firm has “Buy” rating given on Wednesday, March 6 by Cantor Fitzgerald. The stock has “Buy” rating by Ladenburg on Wednesday, March 6. The rating was maintained by JMP Securities with “Buy” on Tuesday, March 12.
More notable recent Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) news were published by: Benzinga.com which released: “Jefferies Sees Opportunity In Marinus Pharmaceuticals (NASDAQ:MRNS): 4 Reasons Why – Benzinga” on March 05, 2019, also Seekingalpha.com with their article: “Marinus Pharma’s ganaxolone shows positive action in mid-stage postpartum depression studies; shares up 35% premarket – Seeking Alpha” published on December 10, 2018, Nasdaq.com published: “Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference – Nasdaq” on February 20, 2019. More interesting news about Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) were released by: Seekingalpha.com and their article: “Cowen sees 94% upside in Aurora Cannabis in premarket analyst action – Seeking Alpha” published on March 05, 2019 as well as Nasdaq.com‘s news article titled: “Pre-Market Most Active for Dec 10, 2018 : AMD, MRNS, QQQ, SQQQ, CRON, AAPL – Nasdaq” with publication date: December 10, 2018.